#	Pagina
attuale pagina	/open-h2020/projects/193184/index.html

Opendata, web and dolomites

FAIR-PARK-II SIGNED

Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Outcomes and
results

FAIR-PARK-II project word cloud

Explore the words cloud of the FAIR-PARK-II project. It provides you a very rough idea of what is the project "FAIR-PARK-II" about.

economics probing baseline patients prototypic deferiprone prompt group treatment rating phenyl dopaminergic catechol de parkinson score oxidative motor effect efficacy nigra biomarkers impacts biological mg reduces detected pd communicable therapy pars disease model diseases 17 academic scores neurodegenerative slows unified cell compacta tetrahydropyridine placebo neuroprotection translational dose movement frequent multicentre demonstrated primarily international levels day clinical weeks health kg primary pilot stress preclinical randomized disorders dfp industrial societal symptomatic moderate chronic substantia wash society conservative trial inhibition radiological linked disorder novo surrogate 2nd induces drug secondary neurons dopamine national modifying models mouse systemic transferase siderosis criterion worldwide antioxidant methyl powerful iron chelation progression total regional followed metabolism excess handicap exposed mitochondrial parallel period brain innovation

Project "FAIR-PARK-II" data sheet

The following table provides information about the project.

Coordinator	CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE Organization address address: AVENUE OSCAR LAMBRET 2 city: LILLE postcode: 59037 website: http://www.chru-lille.fr/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Project website	http://www.fairpark2.eu/
Total cost	8˙263˙202 €
EC max contribution	5˙998˙994 € (73%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-PHC-2014-two-stage
Funding Scheme	RIA
Starting year	2015
Duration (year-month-day)	from 2015-05-01 to 2021-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE Organization address address: AVENUE OSCAR LAMBRET 2 city: LILLE postcode: 59037 website: http://www.chru-lille.fr/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LILLE)	coordinator	2˙662˙169.00
2	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	642˙888.00
3	INSERM - TRANSFERT SA INSERM - TRANSFERT SA Organization address address: RUE WATT 7 city: PARIS postcode: 75013 website: www.inserm-transfert.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	389˙491.00
4	CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL Organization address address: OLSHAUSENSTRASSE 40 city: KIEL postcode: 24118 website: http://www.uni-kiel.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (KIEL)	participant	351˙882.00
5	ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK Organization address address: 5 RUE WATT city: PARIS postcode: 75013 website: www.ecrin.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	331˙848.00
6	UNIVERSITY OF NEWCASTLE UPON TYNE UNIVERSITY OF NEWCASTLE UPON TYNE Organization address address: KINGS GATE city: NEWCASTLE UPON TYNE postcode: NE1 7RU website: http://www.ncl.ac.uk/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (NEWCASTLE UPON TYNE)	participant	313˙370.00
7	STICHTING KATHOLIEKE UNIVERSITEIT STICHTING KATHOLIEKE UNIVERSITEIT Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ website: www.radboudumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (NIJMEGEN)	participant	256˙250.00
8	MEDIZINISCHE UNIVERSITAT INNSBRUCK MEDIZINISCHE UNIVERSITAT INNSBRUCK Organization address address: CHRISTOPH PROBST PLATZ 1 city: INNSBRUCK postcode: 6020 website: www.i-med.ac.at contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (INNSBRUCK)	participant	226˙735.00
9	FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA Organization address address: CARRER ROSSELLO 149 city: BARCELONA postcode: 8036 website: www.fundacioclinic.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	196˙773.00
10	INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES Organization address address: AVENIDA PROF EGAS MONIZ city: LISBOA postcode: 1649 028 website: www.imm.ul.pt contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PT (LISBOA)	participant	187˙083.00
11	UNIVERZITA KARLOVA UNIVERZITA KARLOVA Organization address address: OVOCNY TRH 560/5 city: PRAHA 1 postcode: 116 36 website: www.cuni.cz contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CZ (PRAHA 1)	participant	145˙000.00
12	UNIVERSITAET ULM UNIVERSITAET ULM Organization address address: HELMHOLTZSTRASSE 16 city: ULM postcode: 89081 website: www.uni-ulm.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (ULM)	participant	90˙000.00
13	SORBONNE UNIVERSITE SORBONNE UNIVERSITE Organization address address: 21 RUE DE L'ECOLE DE MEDECINE city: PARIS postcode: 75006 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	82˙550.00
14	PHILIPPS UNIVERSITAET MARBURG PHILIPPS UNIVERSITAET MARBURG Organization address address: BIEGENSTRASSE 10 city: MARBURG postcode: 35037 website: www.uni-marburg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MARBURG)	participant	74˙875.00
15	EBERHARD KARLS UNIVERSITAET TUEBINGEN EBERHARD KARLS UNIVERSITAET TUEBINGEN Organization address address: GESCHWISTER-SCHOLL-PLATZ city: TUEBINGEN postcode: 72074 website: www.uni-tuebingen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (TUEBINGEN)	participant	48˙078.00
16	APO-PHARMA INC CORP APO-PHARMA INC CORP Organization address address: SIGNET DRIVE 150 city: Toronto postcode: M9L 1T9 website: www.apotex.com/ca/en contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CA (Toronto)	participant	0.00
17	UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 Organization address address: Place Jussieu 4 city: PARIS postcode: 75252 website: www.upmc.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	0.00

Map

Project objective

Parkinson’s disease (PD) is a major, chronic, non-communicable disease and the 2nd most frequent neurodegenerative disorder worldwide. Excess iron is primarily detected in the substantia nigra pars compacta, where dopaminergic neurons are exposed to high levels of oxidative stress produced by mitochondrial disorders and dopamine metabolism. Our previous preclinical, translational and pilot clinical studies demonstrated that novel iron chelation therapy with the prototypic drug deferiprone (DFP) (i) induces neuroprotection in cell models of PD via a powerful antioxidant effect, (ii) reduces regional siderosis of the brain, (iii) reduces motor handicap via inhibition of catechol-o-methyl transferase, and (iv) slows the progression of motor handicap in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model and in early PD patients. This project now seeks to demonstrate that conservative iron chelation therapy with moderate-dose DFP (30 mg/kg/day) slows the progression of handicap in de novo PD patients while not affecting systemic parameters. The 9-month, parallel-group, randomized, placebo-controlled, multicentre trial will be followed by a 1-month wash-out period. The primary efficacy criterion will be the change in motor and non-motor handicap scores on the Total Movement Disorders Society Unified Parkinson’s Disease Rating Scale to identify disease-modifying and symptomatic effects. The secondary efficacy criterion will be the change in score between baseline and 40 weeks (i.e. probing the disease-modifying effect only). Potential surrogate radiological and biological biomarkers, health economics and societal impacts will be assessed. 17 national, European and international research and innovation activities will be linked with the project. The study results should prompt academic and industrial research on iron chelation as a disease-modifying treatment in neurodegenerative diseases.

Deliverables

List of deliverables.
Communication and Dissemination tools including website	Websites, patent fillings, videos etc.	2020-02-17 17:47:27

Take a look to the deliverables list in detail: detailed list of FAIR-PARK-II deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	MHD Rami Al Shweiki, Petra Steinacker, Patrick Oeckl, Bastian Hengerer, Adrian Danek, Klaus Fassbender, Janine Diehl-Schmid, Holger Jahn, Sarah Anderl-Straub, Albert C. Ludolph, Carlos SchÃ¶nfeldt-Lecuona, Markus Otto Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia published pages: 137-140, ISSN: 0022-3956, DOI: 10.1016/j.jpsychires.2019.03.019	Journal of Psychiatric Research 113	2020-02-17
2017	Patrick Oeckl, Petra Steinacker, Markus Otto Comparison of Internal Standard Approaches for SRM Analysis of Alpha-Synuclein in Cerebrospinal Fluid published pages: 516-523, ISSN: 1535-3893, DOI: 10.1021/acs.jproteome.7b00660	Journal of Proteome Research 17/1	2020-02-17
2018	Johannes Denk, Felix Oberhauser, Johannes Kornhuber, Jens Wiltfang, Klaus Fassbender, Matthias L. Schroeter, Alexander E. Volk, Janine Diehl-Schmid, Johannes Prudlo, Adrian Danek, Bernhard Landwehrmeyer, Martin Lauer, Markus Otto, Holger Jahn Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls published pages: e0197329, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0197329	PLOS ONE 13/5	2020-02-17
2017	Carina Lehmer, Patrick Oeckl, Jochen H Weishaupt, Alexander E Volk, Janine Diehlâ€Schmid, Matthias L Schroeter, Martin Lauer, Johannes Kornhuber, Johannes Levin, Klaus Fassbender, Bernhard Landwehrmeyer, Martin H Schludi, Thomas Arzberger, Elisabeth Kremmer, Andrew Flatley, Regina Feederle, Petra Steinacker, Patrick Weydt, Albert C Ludolph, Dieter Edbauer, Markus Otto, Adrian Danek, Emily Feneber Polyâ€ GP in cerebrospinal fluid links C9orf72 â€associated dipeptide repeat expression to the asymptomatic phase of ALS / FTD published pages: 859-868, ISSN: 1757-4676, DOI: 10.15252/emmm.201607486	EMBO Molecular Medicine 9/7	2020-02-17
2017	Viviana Carcamo YaÃ±ez, Jens GÃ¶pfert, Markus Otto, Hayrettin Tumani, Andreas Peter, Thomas Joos Development and Validation of an Ultrasensitive Procalcitonin Sandwich Immunoassay published pages: 18, ISSN: 2571-5135, DOI: 10.3390/ht6040018	High-Throughput 6/4	2020-02-17
2018	Francisco Oliveira, Antoine Leuzy, JoÃ£o Castelhano, Konstantinos Chiotis, Steen Gregers Hasselbalch, Juha Rinne, Alexandre MendonÃ§a, Markus Otto, Alberto LleÃ³, Isabel Santana, Jarkko Johansson, Sarah Anderl-Straub, Christine Arnim, Ambros Beer, Rafael Blesa, Juan Fortea, Herukka Sanna-Kaisa, Erik Portelius, Josef Pannee, Henrik Zetterberg, Kaj Blennow, Ana P. Moreira, Antero Abrunhosa, Agneta N Data driven diagnostic classification in Alzheimer\'s disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of AÎ² species published pages: 603-610, ISSN: 2213-1582, DOI: 10.1016/j.nicl.2018.08.023	NeuroImage: Clinical 20	2020-02-17
2019	Shashank Masaldan, Ashley I. Bush, David Devos, Anne Sophie Rolland, Caroline Moreau Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration published pages: 221-233, ISSN: 0891-5849, DOI: 10.1016/j.freeradbiomed.2018.09.033	Free Radical Biology and Medicine 133	2020-02-17
2016	Patrick Oeckl, Fabian Metzger, Magdalena Nagl, Christine A.F. von Arnim, Steffen Halbgebauer, Petra Steinacker, Albert C. Ludolph, Markus Otto Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimerâ€²s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies published pages: 3126-3138, ISSN: 1535-9476, DOI: 10.1074/mcp.m116.059915	Molecular & Cellular Proteomics 15/10	2020-02-17
2018	Minh H. Pham, Elke Warmerdam, Morad Elshehabi, Christian Schlenstedt, Lu-Marie Bergeest, Maren Heller, Linda Haertner, Joaquim J. Ferreira, Daniela Berg, Gerhard Schmidt, Clint Hansen, Walter Maetzler Validation of a Lower Back â€œWearableâ€-Based Sit-to-Stand and Stand-to-Sit Algorithm for Patients With Parkinson\'s Disease and Older Adults in a Home-Like Environment published pages: , ISSN: 1664-2295, DOI: 10.3389/fneur.2018.00652	Frontiers in Neurology 9	2020-02-17
2017	Laetitia Thibault, Olivier Rascol, Jean-Christophe Corvol, Joaquim Ferreira, Luc Defebvre, Dominique Deplanque, RÃ©gis Bordet, Caroline Moreau, David Devos New perspectives on study designs for evaluating neuroprotection in Parkinson\'s disease published pages: 1365-1370, ISSN: 0885-3185, DOI: 10.1002/mds.27055	Movement Disorders 32/10	2020-02-17
2018	Caroline Moreau, James A. Duce, Olivier Rascol, Jean-Christophe Devedjian, Daniela Berg, David Dexter, Z. Ioav Cabantchik, Ashley I. Bush, David Devos Iron as a therapeutic target for Parkinson\'s disease published pages: 568-574, ISSN: 0885-3185, DOI: 10.1002/mds.27275	Movement Disorders 33/4	2020-02-17
2017	Anahita Fathi Kazerooni, Mahnaz Nabil, Mehdi Zeinali Zadeh, Kavous Firouznia, Farid Azmoudeh-Ardalan, Alejandro F. Frangi, Christos Davatzikos, Hamidreza Saligheh Rad Characterization of active and infiltrative tumorous subregions from normal tissue in brain gliomas using multiparametric MRI published pages: , ISSN: 1053-1807, DOI: 10.1002/jmri.25963	Journal of Magnetic Resonance Imaging	2020-02-17
2018	JoÃ£o C.P. Santiago, Markus Otto, Werner Kern, Paul Christian Baier, Manfred Hallschmid Relationship between cerebrospinal fluid concentrations of orexin A/hypocretin-1 and body composition in humans published pages: 26-30, ISSN: 0196-9781, DOI: 10.1016/j.peptides.2018.02.005	Peptides 102	2020-02-17
2017	Anja Hviid Simonsen, Sanna-Kaisa Herukka, Niels Andreasen, Ines Baldeiras, Maria Bjerke, Kaj Blennow, Sebastiaan Engelborghs, Giovanni B. Frisoni, Tomasz Gabryelewicz, Samantha Galluzzi, Ron Handels, Milica G. Kramberger, Agnieszka KulczyÅ„ska, Jose Luis Molinuevo, Barbara Mroczko, Agneta Nordberg, Catarina Resende Oliveira, Markus Otto, Juha O. Rinne, UroÅ¡ Rot, Esen Saka, Hilkka Soininen, Hanne Recommendations for CSF AD biomarkers in the diagnostic evaluationÂ of dementia published pages: 274-284, ISSN: 1552-5260, DOI: 10.1016/j.jalz.2016.09.008	Alzheimer\'s & Dementia 13/3	2020-02-17

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FAIR-PARK-II" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FAIR-PARK-II" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

SBR (2020)

SMART BONE REGENERATION

Read More

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More